Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
OCS | US
1.00
8.20%
Healthcare
Biotechnology
30/06/2024
04/10/2024
13.20
12.48
13.33
12.48
Oculis Holding AG a clinical-stage biopharmaceutical company develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01 a topical dexamethasone formulation which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02 a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca or dry eye disease; and OCS-05 a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders such as glaucoma diabetic retinopathy geographic atrophy and neurotrophic keratitis. The company is based in Zug Switzerland.
View LessPositive Momentum
Strength based on increasing price with high volume
Low 6-Month Volatility (<30%)
High Current Volume and Positive 1-Day Return
Low Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
High Short-term Volatility
Smallcap (300M - 2B USD)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
42.4%1 month
29.3%3 months
29.1%6 months
27.2%-
-
3.87
0.01
0.01
-3.47
-
-
-62.84M
551.04M
551.04M
-
-9.18K
-
-2.00
-58.12
0.56
0.05
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
1.43
Range1M
1.77
Range3M
2.54
Rel. volume
2.15
Price X volume
919.91K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Scholar Rock Holding Corporation | SRRK | Biotechnology | 7.42 | 593.84M | 0.95% | n/a | 50.92% |
Pharming Group N.V. | PHAR | Biotechnology | 8.04 | 545.40M | -0.74% | n/a | 63.43% |
Revance Therapeutics Inc | RVNC | Biotechnology | 5.22 | 543.82M | 0.58% | n/a | -378.95% |
UroGen Pharma Ltd | URGN | Biotechnology | 12.7 | 534.85M | 0.95% | n/a | 326.69% |
4D Molecular Therapeutics Inc | FDMT | Biotechnology | 9.97 | 518.14M | -2.92% | n/a | 2.32% |
Third Harmonic Bio Inc. | THRD | Biotechnology | 12.52 | 514.54M | -0.71% | n/a | 1.40% |
SIGA Technologies Inc | SIGA | Biotechnology | 6.98 | 498.16M | 0.87% | 5.95 | 0.97% |
CorMedix Inc | CRMD | Biotechnology | 8.9 | 497.15M | 7.62% | n/a | 1.29% |
Emergent BioSolutions Inc | EBS | Biotechnology | 9.35 | 494.68M | 1.74% | n/a | 226.97% |
KalVista Pharmaceuticals Inc | KALV | Biotechnology | 11.36 | 490.93M | -4.05% | n/a | 3.62% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
ACCO Brands Corporation | ACCO | Building Products & Equipment | 5.25 | 502.94M | -0.19% | n/a | 174.23% |
Lincoln Educational Services Corporation | LINC | Building Products & Equipment | 11.63 | 366.05M | 0.00% | 47.92 | 88.92% |
ONEWATER MARINE INC. | ONEW | Recreational Vehicles | 21.28 | 334.47M | -4.23% | n/a | 286.96% |
Marine Products Corporation | MPX | Recreational Vehicles | 9.47 | 328.78M | 0.21% | 13.24 | 0.00% |
MCBC Holdings Inc | MCFT | Recreational Vehicles | 17.64 | 292.95M | -0.56% | 35.53 | 26.82% |
CPI Card Group Inc | PMTS | Building Products & Equipment | 23.62 | 261.38M | 4.61% | 17.90 | -621.78% |
Virco Mfg. Corporation | VIRC | Building Products & Equipment | 13.5 | 219.91M | 1.89% | 8.52 | 39.79% |
Kewaunee Scientific Corporation | KEQU | Building Products & Equipment | 31.64 | 90.86M | -0.32% | 5.47 | 19.82% |
Saga Communications Inc | SGA | Broadcasting - Radio | 14 | 87.66M | -1.27% | 14.62 | 7.10% |
REE Automotive Ltd. Class A Ordinary Shares | REE | Recreational Vehicles | 7.64 | 83.40M | -1.93% | n/a | 58.43% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -3.47 | 0.76 | Cheaper |
Ent. to Revenue | - | 3,674.48 | - |
PE Ratio | - | 38.01 | - |
Price to Book | 3.87 | 14.10 | Cheaper |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 29.13 | 74.67 | Lower Risk |
Debt to Equity | 0.01 | -1.82 | Expensive |
Debt to Assets | 0.01 | 0.26 | Cheaper |
Market Cap | 551.04M | 3.73B | Emerging |